|
|
The First Annual Miami General Medical Oncology SymposiumFebruary 22 – 24, 2019, Miami, FL The First Annual Miami General Medical Oncology Symposium
Please note that slides are for review only and not to be repurposed or published. Keynote Dr Porter Dr Kaufman Dr Neelapu Module 1: Colorectal and Gastric Cancer Colorectal Cancer — Dr Fuchs Gastric, Gastroesophageal Junction and Esophageal Cancer — Dr Enzinger Module 2: Hepatocellular Carcinoma Anti-VEGF-Directed Therapy — Dr El-Khoueiry Immune Checkpoint Inhibitors — Dr Greten Module 3: Melanoma Adjuvant Therapy — Dr Lipson Metastatic Disease — Dr Daud Module 4: Chronic Lymphocytic Leukemia (CLL) Newly Diagnosed CLL — Dr Davids Management of Relapsed/Refractory CLL and Investigational Approaches — Dr Jain Module 5: Hodgkin and Non-Hodgkin Lymphomas Follicular Lymphoma — Dr Leonard Mantle Cell Lymphoma and Hodgkin Lymphoma — Dr Moskowitz Module 6: Ovarian Cancer (OC) Current and Future Role of PARP Inhibitors in the Treatment of OC — Dr Coleman Other Recently Approved and Promising Investigational Strategies — Dr Matulonis Module 7: Pancreatic Cancer Neoadjuvant and Adjuvant Therapy — Dr Ko Metastatic Disease — Dr Philip Module 8: ER-Positive, HER2-Negative Breast Cancer (BC) Recent Clinical Trial Results Guiding the Use of Genomic Classifiers in the Management of Early BC; Ongoing Evaluation of CDK4/6 Inhibition in Earlier-Stage Disease — Dr Burstein Sequence and Selection of Systemic Therapy for Patients with ER-Positive Metastatic BC; Novel Agents in Development — Dr Sledge Module 9: HER2-Positive and Triple-Negative BC Triple-Negative BC; PARP Inhibition in the Management of BC — Dr Winer HER2-Positive Disease — Dr O’Shaughnessy Module 10: Acute Myeloid Leukemia Current Testing Algorithms; Treatment for Patients with a Genomic Alteration — Dr Stone Recently Approved and Emerging Therapeutic Approaches — Dr Pollyea Module 11: Prostate Cancer (PC) Nonmetastatic Castration-Resistant PC (CRPC) and Metastatic Hormone-Sensitive PC — Dr Hussain Key Issues in the Treatment of Metastatic CRPC — Dr Sartor Module 12: Renal Cell and Bladder Cancer Renal Cell Cancer — Dr Quinn Urothelial Bladder Cancer — Dr Plimack Module 13: Targeted Treatment of Lung Cancer Management of Non-Small Cell Lung Cancer (NSCLC) with an EGFR Tumor Mutation — Dr Oxnard Other Actionable Abnormalities in NSCLC — Dr Sequist Module 14: Immune Checkpoint Inhibitors in Lung Cancer Locally Advanced NSCLC; Metastatic Small Cell Lung Cancer — Dr Gubens Metastatic NSCLC — Dr Neal Live Poll Results Saturday Sunday Download All |